Drug intelligence / Profile preview

ILC

Development stage: Preclinical
Lead developer: Regenerative Medical Solutions
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

RMS Regenerative Medical Solutions is developing an iPSC-derived Islet-Like Cluster (ILC) cell therapy for the treatment of Type 1 and Type 2 diabetes. The therapy involves differentiating human induced pluripotent stem cells (iPSCs) into clusters containing insulin-producing beta cells, glucagon-producing alpha cells, and somatostatin-producing delta cells, mimicking natural pancreatic islets. It functions as a cell replacement therapy to restore endogenous insulin production and glucose regulation. Both autologous and allogeneic versions are in preclinical development.

Other names: Islet-Like ClustersiPSC-derived Islet-Like Cluster cell therapy

Beyond the preview

Go deeper on ILC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILC.

Explore the full profile